The study focuses on patients who have experienced a Stroke and are in the subacute phase, which means the period of recovery that follows the initial emergency but before long‑term rehabilitation is complete. The medication being tested is a 5 mg oral dispersible tablet of Rimonabant, a drug that blocks a specific receptor in the brain involved in appetite and metabolism. Participants will be randomly assigned to receive either the active tablet or an identical tablet that does not contain the drug (a placebo), and they will take the assigned tablet for a defined period while attending regular clinic visits.
The purpose of the study is to evaluate whether Rimonabant can improve functional independence, meaning the ability to perform everyday activities without assistance. Throughout the trial, researchers will monitor safety by checking for any side effects, changes in vital signs, and overall well‑being. Functional ability will be assessed using simple tools such as the Barthel Index, which measures how well a person can manage basic tasks like dressing, eating, and moving around, as well as other straightforward tests of walking and balance. The study does not involve any experimental procedures beyond taking the study tablets and attending the scheduled check‑ups.
Spain 
